Please click here to check whether you must obtain permission to reproduce this image.

Figure 2. Risk difference in all-cause mortality for randomized, controlled trials of vitamin E supplementation and pooled results for low-dosage (<400 IU/d) and high-dosage (400 IU/d) vitamin E trials. The area of each square is proportional to the inverse of the study variance in the analysis. Horizontal lines represent 95% CIs. ADCS = Alzheimer's Disease Cooperative Study; AREDS = Age-Related Eye Diseases Study; ATBC = Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group; CHAOS = Cambridge Heart Antioxidant Study; DATATOP = Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism; GISSI-Prevenzione = Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardio Prevenzione; HOPE = Heart Outcomes Prevention Evaluation; MIN.VIT.AOX = The Geriatrie/MINéraux, VITamines, et AntiOXydants Network; MRC/BHF HPS = Medical Research Council/British Heart Foundation Heart Protection Study; PPP = Primary Prevention Project; PPS = Polyp Prevention Study; REACT = Roche European American Cataract Trial; SPACE = Secondary Prevention with Antioxidants of Cardiovascular disease in Endstage renal disease; SU.VI.MAX = SUpplementation en VItamines et Minéraux AntioXydants; VECAT = Vitamin E, Cataracts, and Age-Related Maculopathy; WAVE = Women's Angiographic Vitamin and Estrogen.